Monograph
P01AX06 - Atovaquone |
Propably not porphyrinogenic |
PNP |
Rationale
Not significantly metabolised.
Chemical description
Antibiotic used in acute treatment of Pneumocystis carnii- pneumonia (PCP) of moderate severity in patients that cannot tolerate trimethoprim - sulfamethoxazol. Admiistered as oral susspsion 1500 mg daily for 21 days Highly lipophilic substance with restricted bioavailability. Clinically efficient plasma concentration is 15 mg/ml. Excreted in unchanged form in stool. South African list: No data/avoid
IPNet drug reports
Uneventful use reported in 4 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Atovaquon Glenmark 750 mg/5 ml suspensie voor oraal gebruik · Wellvone 750 mg/5 ml suspensie voor oraal gebruik · Wellvone 750 mg/5 ml, suspensie voor oraal gebruik 
Wellvone 750 mg/5 ml susp. buv. 
Atovacuona Glenmark 750 mg/5 ml Suspension Oral efg · WELLVONE 750mg/5ml SUSPENSION ORAL 
Atovaquone · Wellvone 
Atovaquone Glenmark 
Wellvone Suspension 
Wellvone
© NAPOS 2025